Nora L Bedrossian, MD
Internal Medicine · Panorama City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 8 years
- Graduated 2018
Offices
1 location · Innovative Medical Solutions Inc A Medical Group · 37 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bedrossian’s office at (310) 553-5203 to ask if they take your plan before you enroll.
California Medical Board record
Licence A164894 · Current
Licensed to practise in California · since 2019 · expires 2027-08-31 · University of Arizona College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism
Original Medicare doctor bills
$93,287
Medicare paid this office $93,287 for 191 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 110 | $39,578 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 136 | $22,139 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $16,528 | $65 |
Who their Medicare patients are
191 Original Medicare patients in 2024. Average age 73 · Under 65 17% · 85 and older 15% · Women 50% · Also on Medicaid 93% · Health risk score 3.51. Sicker patients than 9 in 10 peers; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 65% · Coronary heart disease 58% · Heart failure 58% · Depression 52% · Dementia 50% · COPD 44% · Atrial fibrillation 29% · Stroke 25% · Cancer 13%.
The office billed $1,184,150, Medicare allowed $118,368 and paid $93,287; for 938 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 191 | 938 | 73 | 3.51 | $1,184,150 | $93,287 |
| 2023 | 38 | 254 | 74 | 4.40 | $298,600 | $24,592 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $14,256 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,086 | $145 |
Medicaid work
$103,262 in 2024
Medicaid paid $103,262 for 2,092 billed services this clinician did in 2024, up to 119 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (45+ min) | 430 | $28,041 |
| Return visit (30+ min) | 423 | $20,390 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 547 | $19,600 |
| Short return visit (20+ min) | 303 | $15,697 |
| 1ST HOSP IP/OBS HIGH 75 | 170 | $9,828 |
| New patient visit (60+ min) | 52 | $5,463 |
| New patient visit (30+ min) | 42 | $1,532 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 60 | $1,133 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 20 | $851 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report | 45 | $726 |
| 2024 | 2,092 | 10 | 119 | $103,262 |
| 2023 | 178 | 3 | 41 | $2,649 |
See the largest Medicaid services in earlier years
2023
| 1ST HOSP IP/OBS HIGH 75 | 30 | $1,581 |
| New patient visit (45+ min) | 101 | $754 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 47 | $313 |
Drugs they prescribed that Part D paid
$409,158
Pharmacies billed $409,158 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 983) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
400 generic and 517 brand-name prescriptions · $409,158 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 132 | $120,992 | $917 |
| Jardiance | 74 | $79,505 | $1,074 |
| Rybelsus | 32 | $33,774 | $1,055 |
| Farxiga | 35 | $32,205 | $920 |
| Trulicity | 16 | $20,899 | $1,306 |
See all 26 drugs
| Ozempic | 132 | $120,992 | $917 |
| Jardiance | 74 | $79,505 | $1,074 |
| Rybelsus | 32 | $33,774 | $1,055 |
| Farxiga | 35 | $32,205 | $920 |
| Trulicity | 16 | $20,899 | $1,306 |
| Mounjaro | 17 | $17,756 | $1,044 |
| Basaglar Kwikpen U-100 | 39 | $15,342 | $393 |
| Januvia | 15 | $14,989 | $999 |
| Tresiba Flextouch U-100 | 13 | $5,258 | $404 |
| Lantus Solostar | 30 | $3,420 | $114 |
| Admelog Solostar | 15 | $2,926 | $195 |
| Humalog Kwikpen U-100 | 19 | $2,099 | $110 |
| Nano 2nd Gen Pen Needle | 17 | $1,352 | $80 |
| Novolog Flexpen | 11 | $1,338 | $122 |
| Ultra-Fine Mini Pen Needle | 18 | $1,266 | $70 |
| Clotrimazole | 27 | $666 | $25 |
| Levothyroxine | 55 | $665 | $12 |
| Nateglinide | 14 | $478 | $34 |
| Metformin | 78 | $387 | $5 |
| Atorvastatin | 38 | $284 | $7 |
| Glimepiride | 29 | $271 | $9 |
| Pioglitazone | 22 | $160 | $7 |
| Gabapentin | 12 | $116 | $10 |
| Glipizide | 19 | $85 | $4 |
| Alendronate | 11 | $85 | $8 |
| Easy Touch Alcohol Prep Pads | 11 | $57 | $5 |
Year by year
| 2024 | 983 | 137 | 0% (0) | 53% | $409,158 |
| 2023 | 195 | 39 | 0% (0) | 37% | $64,321 |
| 2022 | 133 | 31 | 0% (0) | 32% | $19,243 |
| 2021 | 216 | 38 | 0% (0) | None | $28,631 |
| 2020 | 142 | 38 | 0% (0) | None | $8,807 |
| 2019 | 11 | None | 0% (0) | 0% | $68 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Ozempic | 12 | $10,171 | $848 |
| Novolog Flexpen | 12 | $7,358 | $613 |
| Ultra-Fine Nano Pen Needle | 20 | $1,296 | $65 |
| Levothyroxine | 34 | $1,030 | $30 |
2022: 2 drugs
| Levothyroxine | 25 | $687 | $27 |
| Ultra-Fine Nano Pen Needle | 12 | $479 | $40 |
2021: 4 drugs
| Atorvastatin | 19 | $416 | $22 |
| Diclofenac | 15 | $391 | $26 |
| Amlodipine Besylate | 13 | $86 | $7 |
| Furosemide | 12 | $37 | $3 |
2020: 2 drugs
| Diclofenac | 16 | $391 | $24 |
| Atorvastatin | 11 | $143 | $13 |
Money from drug and device companies
$796 in 2025
| 2025 | 9 | 21 | $325 | $796 |
| 2024 | 5 | 8 | None | $166 |
| 2023 | 2 | 2 | None | $148 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Chiesi USA | Mycapssa | $325 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $234 | 10 payments
|
| Novo Nordisk | Rybelsus | $62 | 3 payments
|
| Neurocrine BioSciences | Crenessity | $41 | 2 payments
|
| Teva Pharmaceuticals USA | Uzedy | $36 | 1 payment
|
| Radius Health | None | $31 | 1 payment
|
See all 21 published payments
| Sequel Med Tech | Meals · 2025-12-18 | Twiist | $27 |
| Chiesi USA | Honoraria · 2025-12-09 | Mycapssa | $325 |
| Dexcom | Meals · 2025-12-08 | Dexcom G6 Transmitter | $19 |
| Novo Nordisk | Meals · 2025-11-14 | Rybelsus | $26 |
| Teva Pharmaceuticals USA | Meals · 2025-10-08 | Uzedy | $36 |
| Insulet | Meals · 2025-10-03 | Omnipod | $19 |
| Novo Nordisk | Meals · 2025-09-04 | Wegovy | $16 |
| Dexcom | Meals · 2025-08-28 | Dexcom G6 Transmitter | $24 |
| Neurocrine BioSciences | Meals · 2025-07-18 | Crenessity | $18 |
| Dexcom | Meals · 2025-07-01 | Dexcom G6 Transmitter | $31 |
| Dexcom | Meals · 2025-06-10 | Dexcom G6 Transmitter | $19 |
| Dexcom | Meals · 2025-05-27 | Dexcom G6 Transmitter | $38 |
| Neurocrine BioSciences | Meals · 2025-05-23 | Crenessity | $22 |
| Dexcom | Meals · 2025-05-14 | Dexcom G6 Transmitter | $13 |
| Novo Nordisk | Meals · 2025-05-09 | Ozempic | $21 |
| Radius Health | Meals · 2025-05-03 | None | $31 |
| Dexcom | Meals · 2025-04-29 | Dexcom G6 Transmitter | $21 |
| Tandem Diabetes Care | Meals · 2025-04-23 | T:Slim X2 Insulin Pump With Control-Iq | $22 |
| Dexcom | Meals · 2025-02-11 | Dexcom G6 Transmitter | $24 |
| Dexcom | Meals · 2025-01-28 | Dexcom G6 Transmitter | $22 |
| Dexcom | Meals · 2025-01-07 | Dexcom G6 Transmitter | $22 |
See earlier years (2024, 2023)
2024: $166
| Dexcom | Dexcom G6 Transmitter | $64 | 3 payments
|
| Novo Nordisk | Rybelsus | $34 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $32 | 2 payments
|
| Insulet | Omnipod | $22 | 1 payment
|
| Lilly USA | Mounjaro | $15 | 1 payment
|
2023: $148
| Regeneron Healthcare Solutions | Dupixent | $120 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $28 | 1 payment
|
Professional record
- NPI
- 1649774175
- Licence
- CA A164894California A164894: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 14860 Roscoe Blvd Ste 200, Panorama City, CA, 91402
- NPI first listed
- 2018-03-20
- NPI last updated
- 2023-07-19
- NPI record certified
- 2023-07-19
This is when the NPI record was last certified, not a medical board exam.